BUZZ-Crescent Biopharma rises as global trial for new cancer drug starts

Reuters01:00

** Shares of drugmaker Crescent Biopharma CBIO.O rise 4% to $9.68

** Co says it has begun a global early‑stage trial of CR‑001 for advanced solid tumors

** CR‑001 is an experimental cancer drug designed to help the immune system attack tumors and block blood supply, CBIO says

** Co says study will test safety and how the drug moves and acts in the body before checking for early signs of tumor shrinkage

** Trial to enroll up to 290 patients across the U.S., Europe and Asia Pacific; initial data expected in early 2027, CBIO says

** Co says it has granted China-based cancer‑drug developer Sichuan Kelun-Biotech exclusive rights to develop and sell the drug in Greater China

** Shares down ~52% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2612440859?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-19 01:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612440859","market":"us","top_or_hot":-1,"title":"BUZZ-Crescent Biopharma rises as global trial for new cancer drug starts","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Crescent Biopharma rises as global trial for new cancer drug starts</title></head><body><p>** Shares of drugmaker <span>Crescent Biopharma </span><span>CBIO.O</span> rise 4% to $9.68  </p><p>** Co says it has begun a global early‑stage trial of CR‑001 for advanced solid tumors</p><p>** CR‑001 is an experimental cancer drug designed to help the immune system attack tumors and block blood supply, CBIO says</p><p>** Co says study will test safety and how the drug moves and acts in the body before checking for early signs of tumor shrinkage</p><p>** Trial to enroll up to 290 patients across the U.S., Europe and Asia Pacific; initial data expected in early 2027, CBIO says</p><p>** Co says it has granted China-based cancer‑drug <span>developer Sichuan </span>Kelun-Biotech exclusive rights to develop and sell the drug in Greater China</p><p>** Shares down ~52% in 2025</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Crescent Biopharma rises as global trial for new cancer drug starts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Crescent Biopharma rises as global trial for new cancer drug starts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-19 01:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Crescent Biopharma rises as global trial for new cancer drug starts</title></head><body><p>** Shares of drugmaker <span>Crescent Biopharma </span><span>CBIO.O</span> rise 4% to $9.68  </p><p>** Co says it has begun a global early‑stage trial of CR‑001 for advanced solid tumors</p><p>** CR‑001 is an experimental cancer drug designed to help the immune system attack tumors and block blood supply, CBIO says</p><p>** Co says study will test safety and how the drug moves and acts in the body before checking for early signs of tumor shrinkage</p><p>** Trial to enroll up to 290 patients across the U.S., Europe and Asia Pacific; initial data expected in early 2027, CBIO says</p><p>** Co says it has granted China-based cancer‑drug <span>developer Sichuan </span>Kelun-Biotech exclusive rights to develop and sell the drug in Greater China</p><p>** Shares down ~52% in 2025</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0060","symbol_name":"抗癌","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nL4N3ZE19W:1","article_id":"2612440859","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612440859","pubTimestamp":1771434027,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Crescent Biopharma rises as global trial for new cancer drug starts** Shares of drugmaker Crescent Biopharma CBIO.O rise 4% to $9.68  ** Co says it has begun a global earlystage trial of CR001 for advanced solid tumors** CR001 is an experimental cancer drug designed to help the immune system attack tumors and block blood supply, CBIO says** Co says study will test safety and how the drug moves and acts in the body before checking for early signs of tumor shrinkage** Trial to enroll up to 290 patients across the U.S., Europe and Asia Pacific; initial data expected in early 2027, CBIO says** Co says it has granted China-based cancerdrug developer Sichuan Kelun-Biotech exclusive rights to develop and sell the drug in Greater China** Shares down ~52% in 2025  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0060":"抗癌","LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","LU1934453819.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"A\" (USD) ACC","BK0239":"医药制造","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1979443071.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"AD\" (USDHDG) INC","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","CBIO":"Crescent Biopharma Inc","BK4139":"生物科技","BK1161":"生物科技","002422":"科伦药业","06990":"科伦博泰生物-B"},"translate_title":"随着癌症新药全球试验开始，BUZZ-Crescent Biopharma股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CBIO":0.9,"06990":0.9,"002422":0.9},"content_text":"BUZZ-Crescent Biopharma rises as global trial for new cancer drug starts** Shares of drugmaker Crescent Biopharma CBIO.O rise 4% to $9.68  ** Co says it has begun a global early‑stage trial of CR‑001 for advanced solid tumors** CR‑001 is an experimental cancer drug designed to help the immune system attack tumors and block blood supply, CBIO says** Co says study will test safety and how the drug moves and acts in the body before checking for early signs of tumor shrinkage** Trial to enroll up to 290 patients across the U.S., Europe and Asia Pacific; initial data expected in early 2027, CBIO says** Co says it has granted China-based cancer‑drug developer Sichuan Kelun-Biotech exclusive rights to develop and sell the drug in Greater China** Shares down ~52% in 2025 (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2612440859","isCrawlerRequest":true}